- Home
- Products
MARGENZATM (margetuximab-cmkb)
MARGENZATM (margetuximab-cmkb)
- Medicine Name: Margenza®
- Generic Name: Margetuximab-cmkb
- Dosage Form & Strength: 250 mg/10 mL (25 mg/mL), Single-Dose Vial
- Manufactured By: MacroGenics, Inc.
- FDA Approval Date: December 16, 2020
Margenza is a HER2 receptor antagonist used in combination with chemotherapy for the treatment of metastatic HER2-positive breast cancer in adults who have received two or more prior anti-HER2 therapies, including at least one for metastatic disease.
Recommended Dosage
- 15 mg/kg intravenous infusion every 3 weeks (21-day cycle)
- Initial Dose: Infuse over 120 minutes
- Subsequent Doses: Infuse over 30 minutes
- Continue until disease progression or unacceptable toxicity
On days when both chemotherapy and Margenza are administered, give Margenza after chemotherapy.
⚠️ Cardiac Function: Risk of heart-related complications. Monitor LVEF before starting, every 3 months during treatment, and post-treatment.
⚠️ Infusion-Related Reactions (IRRs): Watch for symptoms like fever, chills, nausea, or shortness of breath. Keep emergency medication/equipment ready.
⚠️ Pregnancy Risk: May cause fetal harm. Verify pregnancy status before starting. Use effective contraception during treatment.
❗Discontinue Permanently: If cardiac dysfunction persists for >8 weeks or dosing is interrupted more than 3 times due to LVEF decline.
✅ Documents Required:
- Doctor’s Prescription
- Patient’s Diagnostic Reports
- Government-issued Photo ID
✅ Where Is It Available?
Margenza is available in:
- India: Mumbai, Delhi, Bangalore, Chennai, Hyderabad, Kolkata, Pune, Ahmedabad, Chandigarh, Jaipur, Lucknow, Noida, and more
- Globally: Through Named Patient Supply (NPS) by Indian Pharma Network (IPN)
📞 To Inquire or Order:
Phone/WhatsApp: +91-99675 15602
Email: info@globalraremeds.com
- Sourced from certified global suppliers (USA, Europe, Canada, Australia)
- Verified by registered pharmacists
- Dispatched from New Delhi, India, securely packed with cold chain support
- Complies with WHO-GDP and ISO 9001:2008 standards
Q: What is the active ingredient in Margenza?
A: Margetuximab-cmkb
Q: What is it used for?
A: Treatment of HER2+ metastatic breast cancer in adults who have progressed after 2+ anti-HER2 therapies.
Q: How is Margenza administered?
A: Intravenous infusion every 3 weeks.
Q: What are the most common side effects?
A: Fatigue, diarrhea, nausea, pyrexia (fever), vomiting, cough, headache, constipation, alopecia, and IRRs.
Q: Is it FDA approved?
A: Yes, approved on December 16, 2020.
Q: How should it be stored?
A: Store at 2°C to 8°C, in original carton to protect from light. Do not freeze or shake.
Q: What is the price of Margenza in India?
A: Contact us at +91-99675 15602 or info@globalraremeds.com for updated pricing.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
